click below
click below
Normal Size Small Size show me how
Naplex HIV
| Question | Answer |
|---|---|
| CD4 count < ___ cells/mm^3 immune system can not fend off OI and certain malignancies. | 200 |
| HIV transmission | infected body fluids (blood, semen, breast milk, vaginal or rectal secretions), mucus membranes and open wounds Commonly unprotected sex and sharing needles |
| CDC screening recommendations | Annual testing for pts who have h/x of other STIs, hepatitis, TB or high-risk activities* Everyone else: once between age 13-64 *sex with multiple partners, sharing needles |
| Acute HIV symptoms | flu-like |
| AIDS criteria | CD4 count < 200 cells/mm^3 OR AIDS-defining condition: OI, cancers, HIV wasting syndrome |
| OraQuick home HIV test can lead to a false negative if testing is done __ | sooner than 3 months from exposure |
| emt/tdf brand vs. emt/taf brand | Truvada vs Descovy |
| Pregnant women can take ART. If not on ART already, start this regimen | 2 NRTIs + INSTI or boosted PI consider alternatives to breastfeed (formula) |
| lamuvidine and __ are interchangeable | emt |
| Do not use in CrCl < 30 | biktarvy, dovato, descovy, truvada |
| complete ART regimen has 2 NRTIs + 1 "base" (INSTI, NNRTI, PI) Most preferred ART regimens contain 2 __ + 1 __ __ is an exception to the rule; it contains 1 __ + 1 __ | 2 NRTIs + 1 INSTI Dovato; 1 NRTI + 1 INSTI |
| what is IRIS and how do we treat | worsening of underlying condition d/t increased immune response after beginning ART; continue ART and treat with anti-infective (OI) |
| NRTIs | Z LATTE zidovudine, lamuvidine, abacavir, TDF, TAF, emtricitabine |
| no renal dose adjustment for this NRTI | abacavir |
| hypersensitivity reactions; screen for HLA-B*5701 before initiation | abacavir |
| All NRTIs have warnings for ___ and __ ; boxed warnings for zidovudine | lactic acidosis, hepatomegaly with steatosis |
| hyperpigmentation of palms of hands and soles of feet | emt |
| what increased risk does TDF carry over TAF | renal impairment, decreased bone mineral density |
| INSTIs | B CRED bictegravir, cabotegravir, raltegravir, elvitegravir, dolutegravir |
| only twice daily INSTI | raltegravir (Isentress) |
| All INSTI side effects | weight gain, insomnia... |
| this class has DDI with polyvalent cations | INSTIs |
| NNRTIs | RED rilpivirine, efavirenz, doravirine |
| requires acidic environment for absorption | rilpivirine and atazanavir |
| do not use with PPIs; separate admin H2RAs and antacids | rilpivirine, atazanavir H2RAs 12 hours before or 4 hours after antacids 2 hours before or 4 hours after can use boosted atazanavir with PPI (separate by 12 hours) |
| these NNRTIs should not be used with strong 3A4 inducers | rilpivirine, doravirine |
| All NNRTIs have warnings for | hepatotoxicity, HSR (SJS/TEN) |
| psychiatric symptoms, CNS effects (dizziness, confusion, abnormal dreams), increased lipids take on empty stomach at night to decrease and sleep through CNS effects | efavirenz |
| PIs | -navir atazanavir, darunavir |
| take PIs with __ | booster (ritonavir, cobicistat) |
| caution with sulfa allergy | darunavir |
| PI warnings | metabolic abnormalities, hepatic dysfunction, HSR, |
| these classes are 3A4 substrates and most are strong inhibitors (DDIs) | PIs and boosters |
| can increase CVD risk | PIs |
| take with food to improve tolerability | booster (ritonavir, cobicistat) |
| binds HIV from biding to CD-4 cells that use CCr5 co-receptor; tropism assay required before starting | maraviroc |
| Start PEP within __ hours and continue for | 72 hours, 28 days |
| PrEP treatment options | Descovy, Truvada, Apretude (cabotegravir) |
| bictegravir/emt/taf | biktarvy |
| dolutegravir/lamuvidine | dovato |
| dolutegravir/lamuvidine/abacavir | triumeq |
| cabotegravir/rilpivirine | Cabenuva |
| Stribild vs Genvoya | TDF vs TAF elvitegravir/cobsicistat/emt/TDF elvitegravir/cobsicistat/emt/TAF |